Skip to Content
AntioxidantsAntioxidants
  • Article
  • Open Access

18 November 2026

24 Pages

Elesclomol and Luminespib Modulate Redox-Related Gene Expression, c-MYC and Apoptosis in Triple-Negative MDA-MB-231 Breast Cancer Cells

,
,
,
,
,
,
,
,
and
1
Department of Biochemistry, College of Science, King Saud University, P.O. Box 22452, Riyadh 11451, Saudi Arabia
2
Department of Anatomy and Stem Cell Unit, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia
3
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
4
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

Abstract

Triple-negative breast cancer (TNBC) lacks targeted therapeutic options, and redox homeostasis and MYC-associated glutathione metabolism may represent a vulnerability. We evaluated the copper ionophore elesclomol and the HSP90 inhibitor luminespib, alone and combined, in MDA-MB-231 cells. Viability after treatment with elesclomol, luminespib, ganetespib or onalespib (0.05–0.2 µM) was measured via alamarBlue assay, and sensitivity was examined in the Genomics of Drug Sensitivity in Cancer (GDSC) dataset. Cells were then treated with elesclomol (0.05 µM), luminespib (0.1 µM) or both for apoptosis analysis (Annexin V-FITC/7-AAD), qPCR (c-MYC, GSS, CAT, SOD1, NOX1, NOS2, TGFB1) and multivariate, network and enrichment analyses. Elesclomol was the most potent compound, reducing viability to approximately 5% of control at 72 h versus 43% for luminespib. Quantification of Annexin V-positive cells across replicates showed an increase from 1.1% in the control group to 11.6% in the elesclomol group, 10.2% in luminespib and 13.2% in the combination groups, respectively (p < 0.0001). All treatments decreased c-MYC and increased GSS expression; elesclomol produced the largest increases in NOS2 and CAT, and the combination in NOX1. Principal component analysis separated the treatment groups (87.1% of variance on PC1 and PC2). Elesclomol had the most pronounced effects across assays. The observed decrease in c-MYC expression and increase in GSS expression suggest a potential association between MYC-related and glutathione-related pathways, warranting further mechanistic investigation.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.